Weather , , 0°C

Spinal Cord Injury Pipeline Advances with 40+ Pharma and Biotech Companies are working on drug profiles

 Breaking News
  • No posts were found

Spinal Cord Injury Pipeline Advances with 40+ Pharma and Biotech Companies are working on drug profiles

August 02
19:38 2021
Spinal Cord Injury Pipeline Advances  with 40+ Pharma and Biotech Companies are working on drug profiles

Spinal Cord Injury Pipeline
DelveInsight’s Spinal Cord Injury pipeline report comprehensive insights into 40+ companies and 40+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It also includes clinical and nonclinical stage products in the pipeline drug profiles. It also assesses therapeutics based on product type, stage, route of administration, and molecule type.

DelveInsight’s Spinal Cord Injury pipeline report comprehensive insights into 40+ companies and 40+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It also includes clinical and nonclinical stage products in the pipeline drug profiles. It also assesses therapeutics based on product type, stage, route of administration, and molecule type.

Some of the Key Highlights from the Spinal Cord Injury Pipeline Report

  • There are currently 40+ drugs in the pipeline for Spinal Cord Injury treatment.

  • The Spinal Cord Injury pipeline comprises therapies that are in different stages of the clinical phase include KP-100IT, ES 135, PMZ-1620, MT 3921, AST-OPC1, FAB117-HC, NEU-2000, ALMB0166, KAND 567, Allogeneic stem cell therapy, and others and are expected to be available for Spinal Cord Injury treatment soon.

  • Key pharmaceutical players which are evaluating their drug candidates for Spinal Cord Injury treatment include Kringle Pharma, Eusol Biotech, Pharmazz, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, Histocell, AmKor Pharma, AlaMab therapeutics, Kancera, Athersys, among others.

  • In September 2019, the Japanese Ministry of Health, Labour, and Welfare designated HGF (KP-100IT) as an orphan drug for acute spinal cord injury.

  • GTX Medical and NeuroRecovery Technologies announced their merger in October 2019 to form a leading global company dedicated to developing novel neuromodulation therapies to improve the functional recovery of people with Spinal Cord Injuries (SCI). 

  • Allogeneic stem cell therapy is being developed and investigated in preclinical studies by Athersys for Spinal Cord Injury treatment.

Request for the sample to get an overview of pipeline landscape @ Spinal Cord Injury Pipeline  

Spinal Cord Injury: Overview

Traumatic damage to the spinal cord or nerves at the end of the spinal canal is referred to as spinal cord injury. This has an impact on the transmission of sensory and motor signals across the lesion site. Spinal cord injury is a debilitating neurological condition that has a significant socioeconomic impact on both affected individuals and the healthcare system. There are two types of spinal cord injuries: incomplete and complete injury.

Spinal Cord Injury Diagnosis

The goal of diagnosis is to determine the extent of neurological injury, the degree of residual sensory and motor function, and any complications. Imaging technology is an important part of the chronic spinal cord injury diagnostic process. MRI scans are the gold standard for imaging neurological tissues like the spinal cord, ligaments, discs, and soft tissues.

Spinal Cord Injury Treatment

Individuals suffering from Spinal Cord Injuries or disorders require multidisciplinary care management in order to achieve the best possible health outcomes. Chronic Spinal Cord Injury treatments aim to avoid or improve pathophysiological mechanisms such as glial scar formation, demyelination, and astrogliosis. 

Spinal Cord Injury Pipeline Analysis: Drug Profiles

KP-100IT: Kringle Pharma

Product Description

HGF (KP-100IT) protects neurons and stimulates axon elongation, therefore it could be used as a Spinal Cord Injury treatment. Currently, it is being developed and investigated in Phase III clinical trials for Spinal Cord Injury by Kringle Pharma. 

Phase III

NCT04475224: Kringle Pharma began a non-randomized, multicenter, and confirmatory study of KP-100IT intrathecal administration in subjects with acute spinal cord injury in July 2020. This is a non-randomized, multicenter, confirmatory trial in people with acute spinal cord injuries using intrathecal administration of KP-100IT, a code for HGF (Hepatocyte Growth Factor) formulation for intrathecal injection.

For more information on the emerging drugs and companies, visit Spinal Cord Injury Clinical Trials 

Spinal Cord Injury Pipeline Therapies and Key Companies 

  • KP-100IT: Kringle Pharma

  • ES 135: Eusol Biotech

  • PMZ-1620: Pharmazz

  • MT 3921: Mitsubishi Tanabe Pharma

  • AST-OPC1: Lineage Cell Therapeutics

  • FAB117-HC: Histocell

  • NEU-2000: AmKor Pharma

  • ALMB0166: AlaMab therapeutics

  • KAND 567: Kancera

  • Allogeneic stem cell therapy: Athersys

Spinal Cord Injury Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Spinal Cord Injury Key Players: Kringle Pharma, Eusol Biotech, Pharmazz, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, Histocell, AmKor Pharma, AlaMab therapeutics, Kancera, Athersys,among others

Spinal Cord Injury Pipeline Therapies: KP-100IT, ES 135, PMZ-1620, MT 3921, AST-OPC1, FAB117-HC, NEU-2000, ALMB0166, KAND 567, Allogeneic stem cell therapy, and others

Table of Contents 

1.

Introduction

2.

Executive Summary

3.

Spinal Cord Injury: Overview

4.

Spinal Cord Injury- Analytical Perspective In-depth Commercial Assessment

5.

Spinal Cord Injury Pipeline Therapeutics

6.

Spinal Cord Injury Late Stage Products (Phase III)

7.

Spinal Cord Injury Mid Stage Products (Phase  II)

8.

Spinal Cord Injury Early Stage Products (Phase  I/II)

9.

Spinal Cord Injury Early Stage Products (Phase I)

10.

Spinal Cord Injury Pre-clinical and Discovery Stage Products

11.

Spinal Cord Injury Therapeutics Assessment

12.

Spinal Cord Injury  Inactive Products

13.

Spinal Cord Injury Company-University Collaborations (Licensing/Partnering) Analysis

14.

Spinal Cord Injury Key Companies

15.

Spinal Cord Injury Key Products

16.

Spinal Cord Injury- Unmet Needs

17.

Spinal Cord Injury- Market Drivers and Barriers

18.

Spinal Cord Injury- Future Perspectives and Conclusion

19.

Spinal Cord Injury Analyst Views

20.

Appendix

21.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Key questions answered in the Spinal Cord Injury Pipeline Report

  • What are the treatment options for Spinal Cord injury?

  • How many pharmaceutical companies are working on cures for Spinal Cord injury?

  • Which of these firms’ pharmaceuticals is the most widely used?

  • How many Spinal Cord injury medications does each company make in total?

  • How many drugs in the Spinal Cord injury pipeline are in the early, middle, or late phases of development?

  • How many of the in-development therapies can be used alone or in combination with other treatments?

  • What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices that affect Spinal Cord injury?

Related Reports

Spinal Muscular Atrophy Pipeline Insights

Get a comprehensive analysis of Spinal Muscular Atrophy pipeline therapies and key companies including Kowa, Scholar Rock, Biogen, Exicure, AveXis, Novartis Pharmaceuticals, Catalyst Pharmaceuticals, ReveraGen Biopharma, Translate Bio, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles

Calendar

November 2021
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Categories